Income Statement
CONNECT BIOPHARMA HOLDINGS LTD
CNTB
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY |
|---|---|---|
|
Revenue
|
0.10 | 26.03 |
|
Cost of Revenue
|
- | - |
|
Gross Profit
|
0.10 | 26.03 |
|
Operating Expenses
|
58.14 | 48.49 |
|
Research & Development
|
37.80 | 29.26 |
|
Selling, General & Administrative
|
20.34 | 19.23 |
|
Other Operating Expenses
|
- | - |
|
Operating Income
|
-58.04 | -22.45 |
|
Non-Operating Income
|
2.79 | 7.05 |
|
Interest Income
|
- | - |
|
Interest Expense
|
- | - |
|
Other Non-Op Income / Expense
|
0.52 | -13.51 |
|
Income Before Tax
|
-55.28 | -15.41 |
|
Income Tax Expense
|
0.20 | 0.22 |
|
Non-Controlling Interest
|
- | - |
|
Net Income
|
-55.48 | -15.63 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY |
|---|---|---|
|
Depreciation & Amortization
|
- | - |
|
EBITDA
|
-57.33 | -21.79 |
|
Earnings Per Share (Basic)
|
-1.00 | -0.28 |
|
Diluted EPS
|
-1.00 | -0.28 |
|
Weighted Average Shares
|
55.66 | 55.21 |
|
Diluted Weighted Avg Shares
|
55.66 | 55.21 |
|
Comprehensive Income
|
-55.01 | -16.29 |